Richard B. Stead
CTI BioPharma (Italy)(IT)
Publications by Year
Research Areas
Erythropoietin and Anemia Treatment, Immunotherapy and Immune Responses, Platelet Disorders and Treatments, Cervical Cancer and HPV Research, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Erythropoietin for the Treatment of Porphyria Cutanea Tarda in a Patient on Long-Term Hemodialysis(1990)375 cited
- → A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia(2009)156 cited
- → Strong vaccine responses during chemotherapy are associated with prolonged cancer survival(2020)126 cited
- → Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers(2006)110 cited
- → Pegfilgrastim Administered in an Abbreviated Schedule, Significantly Improved Neutrophil Recovery after High-Dose Radiation-Induced Myelosuppression in Rhesus Macaques(2012)56 cited
- → Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model(2007)55 cited
- → Prevention of Thrombocytopenia and Neutropenia in a Nonhuman Primate Model of Marrow Suppressive Chemotherapy by Combining Pegylated Recombinant Human Megakaryocyte Growth and Development Factor and Recombinant Human Granulocyte Colony-Stimulating Factor(1997)50 cited
- → Heterogeneity of heparin lots associated with thrombocytopenia and thromboembolism(1984)42 cited
- → Treatment of Thrombocytopenia in Chimpanzees Infected With Human Immunodeficiency Virus by Pegylated Recombinant Human Megakaryocyte Growth and Development Factor(1998)42 cited
- → A comparison of therapeutic schedules for administering granulocyte colony-stimulating factor to nonhuman primates after high-dose chemotherapy(1992)31 cited